These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 776529)

  • 1. Dosage form performance: a major factor in clinical medicine.
    Dittert LW
    Conn Med; 1976 May; 40(5):333-7. PubMed ID: 776529
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspects of bioavailability and bioequivalence revision: possible implications on clinical pharmacology.
    Glasser AC
    Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):449-52. PubMed ID: 3683019
    [No Abstract]   [Full Text] [Related]  

  • 3. When do differences in dissolution profiles predict clinical problems?
    Ngo SN
    J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660
    [No Abstract]   [Full Text] [Related]  

  • 4. Some effects of drug laws and regulations on the practice of medicine, with particular emphasis on inflammatory bowel disease.
    Goldstein F
    Am J Gastroenterol; 1988 Oct; 83(10):1091-7. PubMed ID: 3421219
    [No Abstract]   [Full Text] [Related]  

  • 5. Generic substitution.
    Raymond RA
    Nebr Med J; 1989 Jul; 74(7):180-1. PubMed ID: 2761658
    [No Abstract]   [Full Text] [Related]  

  • 6. Aspects for bioavailability and bioequivalence revision: possible implications on clinical pharmacology.
    Ritschel WA
    Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):453-9. PubMed ID: 3683020
    [No Abstract]   [Full Text] [Related]  

  • 7. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
    Rajaram L; Roy SK; Skerjanec A
    Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of bioequivalence trials. From analysis to statistic trials].
    Houin G
    Therapie; 1993; 48(4):289-95. PubMed ID: 8128417
    [No Abstract]   [Full Text] [Related]  

  • 9. Levothyroxine dosage and the limitations of current bioequivalence standards.
    Hennessey JV
    Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756
    [No Abstract]   [Full Text] [Related]  

  • 10. Bioavailability and bioequivalence requirements: abbreviated applications. Final Rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(244):77668-75. PubMed ID: 12492102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What are narrow therapeutic index drugs?
    Levy G
    Clin Pharmacol Ther; 1998 May; 63(5):501-5. PubMed ID: 9630822
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA problems with medications in the marketplace: I.
    Archambault GF
    Hosp Formul; 1976 Apr; 11(4):224. PubMed ID: 1037449
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel methods to assess bioequivalence.
    Karalis V; Symillides M; Macheras P
    Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):79-88. PubMed ID: 21118059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview.
    Ereshefsky L; Jann MW; Saklad SR; Davis CM
    J Clin Psychiatry; 1986 Sep; 47 Suppl():6-15. PubMed ID: 3528134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of biopharmaceutical parameters in drug development (author's transl)].
    Thoma K
    Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dilantin vs generic phenytoin sodium.
    Med Lett Drugs Ther; 1980 Jun; 22(12):49-50. PubMed ID: 7374622
    [No Abstract]   [Full Text] [Related]  

  • 17. Bioequivalence/bioavailability retention samples.
    Ransom C
    Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218
    [No Abstract]   [Full Text] [Related]  

  • 18. Importance of biopharmaceutics and pharmacokinetics in clinical medicine.
    Cabana BE
    Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and opportunities in animal drug development: a regulatory perspective.
    Lathers CM
    Nat Rev Drug Discov; 2003 Nov; 2(11):915-8. PubMed ID: 14560318
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].
    Schnieders B
    Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.